active molecules such as enzymes or non histone proteins the hdac inhibitor agents can be brought in the form of pharmaceutically acceptable salts as such pharmaceutically acceptable salts may be used so long as they do not adversely affect the desired pharmacological effects of the compounds the selection and production can be performed by those skilled in the art examples of pharmaceutically acceptable salts include alkali metal salts such as sodium salt or a potassium salt alkaline earth metal salts such as calcium salt or a magnesium salt salts with an organic base such as an ammonium salt or a salt with an organic base such as a triethylamine salt or an ethanolamine salt the therapeutic composition of the present invention may be administered orally or non orally in the case of oral administration they may be administered in the form of soft and hard capsules tablets granules powders solutions suspensions mouth wash or the like in the case of non oral administration they may be administered in the form of creams ointments gels lotions patches suppositories liposome formations injection solution eye drops nasal spray pulmonary inhalants drip infusion formulations enema or the like whereby continued membrane absorption can be maintained in the form of solid viscous liquid bioadhesive substance or suspension the selection of the.